Gossamer Enters Global Collaboration and License Agreement Valued at $486M

Biopharmaceutical company Gossamer Bio (Nasdaq: GOSS) has entered a global collaboration and license agreement with the Chiesi Farmaceutici S.p.A (Chiesi Group), an international, research-focused biopharmaceutical group. Together, the companies will develop and commercialize seralutinib, an inhaled dry powder treatment for the potential treatment of pulmonary hypertension and interstitial lung disease (PH-ILD). The company’s share price rose slightly in response to the news on Monday morning, and its market cap stands at $168.08 million.

Under the terms of the agreement, Gossamer will receive $160 million in development reimbursement payment and is eligible to receive up to $146 million in regulatory and $180 million in sales milestones. Gossamer will continue to lead global development of seralutinib in  pulmonary arterial hypertension (PAH) and PH-ILD and will be financially responsible for its Phase 3 PROSERA Study in

Gossamer and Chiesi plan to initiate a Phase 3 Trial of Seralutinib in additional indications with high unmet need in mid-2025.

Faheem Hasnain, Co-Founder, Chairman and CEO of Gossamer, commented, “This partnership with Chiesi allows us to meaningfully deepen and rapidly accelerate our investment in seralutinib as a potential treatment for PAH, PH-ILD, and other indications of high unmet medical need. We are particularly thrilled that this collaboration enables seralutinib to move directly into a Phase 3 trial in PH-ILD, an indication with a paucity of available treatments, and a disease which we believe seralutinib is specifically designed to address.”

PAH affects approximately 30,000 to 50,000 people in the US, and a similar number in Europe. Median 5-year overall survival rate for patients with PAH is approximately 57%. PH-ILD affects approximately 60,000-100,000 patients in the US and there is only one approved therapy. Median 5-year overall survival rate for patients with PH-ILD is approximately 23%.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.

About Chiesi Group

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. With over 85 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

For further information please visit www.chiesi.com

Share This Article


About the Author

Gossamer Enters Global Collaboration and License Agreement Valued at $486M

Catie Corcoran

Biotech Editor